ISSN: 1859 - 2872
Follow up shorterm and longterm side-effects of FOLFOX4 regimen as adjuvant chemotherapy for colorectal cancer
Main Article Content
Keywords
FOLFOX4 regimen, colorectal cancer, adjuvant chemotherapy
Abstract
Objective: Follow-up side-effects of FOLFOX4 regimen in adjuvant chemotherapy for colorectal cancer (CRC). Subject and method: Investigating 85 resected CRC patients treated with FOFOX4 regimen as adjuvant chemotherapy in A6 Department of 108 Military Central Hospital from 1/2009. Result: The common side-effects was recoverable and accumulative hand-foot syndrome and peripheral phlebitis with 47.5% and 20% after 12 cycles, and decrease after chemotherapy finished 6 months at 14.4% and 6.2%. Almost patient recovered from toxicity after two years of chemotherapy. Conclusion: The toxicities of FOLFOX4 regimen is acceptable. Peripheral sensory neuropathy is dose-limited toxicity.
Article Details
References
1. Nguyễn Bá Đức (2007) Chẩn đoán và điều trị bệnh ung thư, Nhà xuất bản y học.
2. Nguyễn Thu Hương, Nguyễn Tuyết Mai, Lê Văn Quảng, Phạm Cẩm Hương (2009) Đánh giá hiệu quả của phác đồ FOLFOX 4 trong điều trị UTĐTT giai đoạn muộn tại Bệnh viện K từ tháng 01/2006 đến tháng 6/2008. Y học thực hành (664) – 6/2009.
3. Trần Thắng (2002) Đánh giá kết quả hóa trị liệu trong ung thư biểu mô tuyến đại trực tràng tại bệnh viện K từ 1997 đến 2002. Luận văn Thạc sĩ Y học, 2002.
4. NCCN guidelines (2020) Colon and rectal cancer. Version 2.2011. Version 4.2020
5. Thierry A, Corrado B, Matilde N (200) Improved overall survival with Oxaliplatin, Fluorouracil, and Leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial, Journal of clinical oncology, Volume 27, 7.2009.
6. Jacek AK, Stephanie R, Land, Reena S (2006) Cecchini: Validation of a self-reported neurotoxicity scale in patients with operable colon cancer receiving oxaliplatin. Quality of Life Outcomes – Volume 4 – 9/2006.
7. Asan Medical Center (2008) The cancer chemotherapeutic handbook, six edition, 2008.
8. Berger DP, Engelhardt M, Henß H (2008) Mertelsmann R (2008I Concise Manual of Hematology and Oncology, Springer.
9. WHO (2000) Classification of tumors: Pathology and genetics of tumor of degestic system, chapter IV, IARC.
10. Edge SB, Compton CC (2010) The American Joint Committee on Cancer: Cancer staging manual seventh edition, chapter 14.
2. Nguyễn Thu Hương, Nguyễn Tuyết Mai, Lê Văn Quảng, Phạm Cẩm Hương (2009) Đánh giá hiệu quả của phác đồ FOLFOX 4 trong điều trị UTĐTT giai đoạn muộn tại Bệnh viện K từ tháng 01/2006 đến tháng 6/2008. Y học thực hành (664) – 6/2009.
3. Trần Thắng (2002) Đánh giá kết quả hóa trị liệu trong ung thư biểu mô tuyến đại trực tràng tại bệnh viện K từ 1997 đến 2002. Luận văn Thạc sĩ Y học, 2002.
4. NCCN guidelines (2020) Colon and rectal cancer. Version 2.2011. Version 4.2020
5. Thierry A, Corrado B, Matilde N (200) Improved overall survival with Oxaliplatin, Fluorouracil, and Leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial, Journal of clinical oncology, Volume 27, 7.2009.
6. Jacek AK, Stephanie R, Land, Reena S (2006) Cecchini: Validation of a self-reported neurotoxicity scale in patients with operable colon cancer receiving oxaliplatin. Quality of Life Outcomes – Volume 4 – 9/2006.
7. Asan Medical Center (2008) The cancer chemotherapeutic handbook, six edition, 2008.
8. Berger DP, Engelhardt M, Henß H (2008) Mertelsmann R (2008I Concise Manual of Hematology and Oncology, Springer.
9. WHO (2000) Classification of tumors: Pathology and genetics of tumor of degestic system, chapter IV, IARC.
10. Edge SB, Compton CC (2010) The American Joint Committee on Cancer: Cancer staging manual seventh edition, chapter 14.
Article Sidebar
How to Cite
Pham Thi TuyetN., Bui ThuP., & Nguyen ThiT. (2020). Follow up shorterm and longterm side-effects of FOLFOX4 regimen as adjuvant chemotherapy for colorectal cancer. Tạp Chí Y Dược lâm sàng 108, 15(6), 43-47. Retrieved from https://tcydls108.benhvien108.vn/index.php/YDLS/article/view/633